The Wall Street Journal discussed the new insomnia sleep drug, suvorexant, scheduled to hit shelves in the coming months with NeuroTrials CEO & Chair of the National Sleep Foundation, Dr. Russell Rosenberg.
An estimated 25% or more Americans face a bout of insomnia in a given year, and at least 1 in 10 suffers the chronic form of the disorder, routinely facing sleepless nights, according to the Centers for Disease Control and Prevention.
“There’s a need for more drugs,” said Russell Rosenberg, chairman of the National Sleep Foundation. Current drugs don’t work for everyone, and a push to lower doses amid safety concerns has led to patients “coming in and saying it’s not working as well,” said Dr. Rosenberg..
To read the full article, click here.